Cite
HARVARD Citation
Long, G. et al. (2019). Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet oncology. 20 (7), pp. 961-971. [Online].